Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 50 articles: HTML format

Single Articles

August 2025
1. HUANG J
   Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib.
   J Clin Oncol. 2025 Aug 21:JCO2500967. doi: 10.1200/JCO-25-00967.
   PubMed    
   
   
   
2. PEROL M, Li W, Lai RK, Zhou C, et al
   Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
   J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
   PubMed    
   
   
   
3. COOPER BT, Kondziolka D
   Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
   J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
   PubMed    
   
   
   
4. LASSMAN AB, Polley MC, Iwamoto FM, Sloan AE, et al
   Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
   J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618.
   PubMed     Abstract available
   
   
   July 2025
5. AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al
   Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
   J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.
   PubMed     Abstract available
   
   
   June 2025
6. BLAKELEY J, Mohile NA, Messersmith H, Lassman AB, et al
   Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
   J Clin Oncol. 2025;43:2129-2133.
   PubMed     Abstract available
   
   
   April 2025
7. SPERDUTO PW, Marqueen KE, Chang E, Li J, et al
   Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.
   J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351.
   PubMed     Abstract available
   
   
   March 2025
8. WEISS SA, Djureinovic D, Wei W, Tran T, et al
   Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
   J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219.
   PubMed     Abstract available
   
   
   January 2025
9. KACIMI SEO, Dehais C, Feuvret L, Chinot O, et al
   Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
   J Clin Oncol. 2025;43:329-338.
   PubMed     Abstract available
   
   
   
10. HUANG RY, Youssef G, Nelson T, Wen PY, et al
    Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953.
    PubMed     Abstract available
    
    
    November 2024
11. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    PubMed    
    
    
    
12. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    PubMed    
    
    
    October 2024
13. 
    Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
    J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
    PubMed    
    
    
    September 2024
14. FORST DA, Podgurski AF, Strander SM, Whitman JD, et al
    NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors.
    J Clin Oncol. 2024 Sep 16:JCO2400065. doi: 10.1200/JCO.24.00065.
    PubMed     Abstract available
    
    
    August 2024
15. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    PubMed     Abstract available
    
    
    
16. JENG MY, Yu HA
    Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy.
    J Clin Oncol. 2024;42:2727-2730.
    PubMed    
    
    
    
17. LIN FY, Stuckert A, Tat C, White M, et al
    Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
    J Clin Oncol. 2024;42:2769-2779.
    PubMed     Abstract available
    
    
    July 2024
18. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    PubMed     Abstract available
    
    
    June 2024
19. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    PubMed    
    
    
    
20. KOTECHA R, Schiff D, Chakravarti A, Fleming JL, et al
    Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.
    J Clin Oncol. 2024 Jun 4:JCO2302195. doi: 10.1200/JCO.23.02195.
    PubMed     Abstract available
    
    
    
21. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    PubMed     Abstract available
    
    
    
22. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    PubMed     Abstract available
    
    
    
23. MIKOLAJEWICZ N, Yee PP, Bhanja D, Trifoi M, et al
    Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application.
    J Clin Oncol. 2024;42:1961-1974.
    PubMed     Abstract available
    
    
    March 2024
24. XIAO H, Vaidya R, Hershman DL, Unger JM, et al
    Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
    J Clin Oncol. 2024 Mar 27:JCO2301777. doi: 10.1200/JCO.23.01777.
    PubMed     Abstract available
    
    
    February 2024
25. MARGOL AS, Molinaro AM, Onar-Thomas A, Resnick A, et al
    Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
    J Clin Oncol. 2024 Feb 23:JCO2301084. doi: 10.1200/JCO.23.01084.
    PubMed     Abstract available
    
    
    
26. WU J, Heidelberg RE, Gajjar A
    Adolescents and Young Adults With Cancer: CNS Tumors.
    J Clin Oncol. 2024;42:686-695.
    PubMed     Abstract available
    
    
    
27. ARRILLAGA-ROMANY I, Gardner SL, Odia Y, Aguilera D, et al
    ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
    J Clin Oncol. 2024 Feb 9:JCO2301134. doi: 10.1200/JCO.23.01134.
    PubMed     Abstract available
    
    
    December 2023
28. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    
29. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    PubMed    
    
    
    
30. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    PubMed     Abstract available
    
    
    November 2023
31. HAAS-KOGAN DA, Aboian MS, Minturn JE, Leary SES, et al
    Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    J Clin Oncol. 2023 Nov 17:JCO2301838. doi: 10.1200/JCO.23.01838.
    PubMed     Abstract available
    
    
    
32. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed     Abstract available
    
    
    
33. FRIEDMAN HS, Prados MD, Wen PY, Mikkelsen T, et al
    Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4945-4952.
    PubMed     Abstract available
    
    
    
34. MELLINGHOFF IK
    Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4943-4944.
    PubMed    
    
    
    October 2023
35. LEWIS KL, Jakobsen LH, Villa D, Smedby KE, et al
    High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2023 Oct 5:JCO2300365. doi: 10.1200/JCO.23.00365.
    PubMed     Abstract available
    
    
    September 2023
36. WEN PY, van den Bent M, Youssef G, Cloughesy TF, et al
    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    J Clin Oncol. 2023 Sep 29:JCO2301059. doi: 10.1200/JCO.23.01059.
    PubMed     Abstract available
    
    
    
37. BANU MA, McKhann GM
    Maximizing Extent of Resection for Noneloquent Glioblastoma: Fluorescent Dye or Intraoperative Magnetic Resonance Imaging?
    J Clin Oncol. 2023 Sep 18:JCO2300963. doi: 10.1200/JCO.23.00963.
    PubMed    
    
    
    
38. RAHMAN R, Trippa L, Lee EQ, Arrillaga-Romany I, et al
    Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
    J Clin Oncol. 2023 Sep 18:JCO2300493. doi: 10.1200/JCO.23.00493.
    PubMed     Abstract available
    
    
    August 2023
39. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    PubMed     Abstract available
    
    
    
40. LU BY, Goldberg SB
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Aug 21:JCO2301323. doi: 10.1200/JCO.23.01323.
    PubMed    
    
    
    
41. NADAL E, Rodriguez-Abreu D, Simo M, Massuti B, et al
    Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
    J Clin Oncol. 2023 Aug 21:JCO2202561. doi: 10.1200/JCO.22.02561.
    PubMed     Abstract available
    
    
    June 2023
42. RODER C, Stummer W, Coburger J, Scherer M, et al
    Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.
    J Clin Oncol. 2023 Jun 19:JCO2201862. doi: 10.1200/JCO.22.01862.
    PubMed     Abstract available
    
    
    
43. NEGRAO MV, Spira AI, Heist RS, Janne PA, et al
    Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
    J Clin Oncol. 2023 Jun 16:JCO2300046. doi: 10.1200/JCO.23.00046.
    PubMed     Abstract available
    
    
    
44. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    PubMed     Abstract available
    
    
    May 2023
45. WARREN KE, Vezina G, Krailo M, Springer L, et al
    Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.
    J Clin Oncol. 2023 May 1:JCO2201777. doi: 10.1200/JCO.22.01777.
    PubMed     Abstract available
    
    
    April 2023
46. HSU TW, Liang CS, Tsai SJ, Bai YM, et al
    Risk of Major Psychiatric Disorders Among Children and Adolescents Surviving Malignancies: A Nationwide Longitudinal Study.
    J Clin Oncol. 2023;41:2054-2066.
    PubMed     Abstract available
    
    
    
47. YOUSSEF G, Rahman R, Bay C, Wang W, et al
    Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    J Clin Oncol. 2023 Apr 7:JCO2201579. doi: 10.1200/JCO.22.01579.
    PubMed     Abstract available
    
    
    March 2023
48. MUTTER JA, Alig SK, Esfahani MS, Lauer EM, et al
    Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    J Clin Oncol. 2023;41:1684-1694.
    PubMed     Abstract available
    
    
    February 2023
49. DIEZ VALLE R
    Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.
    J Clin Oncol. 2023 Feb 28:JCO2202428. doi: 10.1200/JCO.22.02428.
    PubMed    
    
    
    January 2023
50. GROMMES C
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.